We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -78.00 | -0.71% | 10,946.00 | 10,946.00 | 10,948.00 | 10,966.00 | 10,822.00 | 10,882.00 | 199,909 | 09:35:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.49 | 169.65B |
From Apr 2019 to Apr 2024
By Dieter Holger
AstraZeneca PLC and GlaxoSmithKline PLC have teamed up with the University of Cambridge to combat shortages of Covid-19 tests, the companies said Tuesday.
The British drug companies said they would set up a laboratory at the university to develop "alternative chemical reagents for test kits in order to help overcome current supply shortages."
"While diagnostic testing is not part of either company's core business, we are moving as fast as we can to help where possible," the companies said.
In late March, GSK joined a coalition of drugmakers who agreed to share their "proprietary libraries of molecular compounds" for screening with the Covid-19 Therapeutics Accelerator, which was launched by the Bill & Melinda Gates Foundation, Mastercard Inc. and U.K.-based nonprofit Wellcome.
That effort could result in human or animal trials in as little as two months, the Gates Foundation said at the time.
Write to Dieter Holger at dieter.holger@wsj.com; @dieterholger
(END) Dow Jones Newswires
April 07, 2020 09:15 ET (13:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
